Dr Roberto Iacovelli brings you his interpretation of the data when deciding upon the best approach to treatment sequencing in mRCC.
Dr Roberto Iacovelli brings you his interpretation of the data when deciding upon the best approach to treatment sequencing in mRCC.
Dr Roberto Iacovelli studied medicine at the “Sapienza” University of Rome, Italy. At the same University, he specialized in medical oncology and had the PhD in molecular medicine and human pathology. He has international experience as a fellow at the Institute Gustave Roussy in France and as an oncologist in main referral oncological centres in Italy. Currently, he is a medical oncologist at the University Hospital of Verona, Italy. His research activities focus on metastatic renal cell carcinoma, prostate, and bladder cancer. His major interest is in predictive and prognostic factors in GU cancers as well as the sequence of therapy in renal cancer. He has published more than one hundred papers in international peer-reviewed journals and several abstracts at international conferences on these topics. Dr Iacovelli has received many national and international awards, such as the ASCO Cancer Foundation Merit Award in 2011 and the best poster award at the ESMO congress in 2012.
Astellas, Ipsen, Janssen, Merck, Pfizer and Sanofi.
Optimising treatment strategies and AE management
Navigating common treatment scenarios in HER2-mutant non-small cell lung cancer
An overview of the EMERALD subgroup analyses
A medical oncologist and a pathologist share their perspectives on best practices in identifying HER2-directed NSCLC
Survey findings presented at ONS 2025 and published in the journal Healthcare